Rheumatoid arthritis-interstitial lung disease shows particularly high risk <\/p>\n<\/h3>\n
By Lori Solomon HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
FRIDAY, Aug. 9, 2024 (HealthDay News) — Rheumatoid arthritis (RA) is associated with a significantly increased risk for lung cancer, according to a study published online July 28 in\u00a0Arthritis & Rheumatology<\/em>.<\/p>\n Rebecca T. Brooks, M.D., from the Mayo Clinic in Rochester, Minnesota, and colleagues evaluated lung cancer risk in people with RA and RA-interstitial lung disease (ILD). The analysis included 72,795 Veterans Health Administration patients with RA and 633,937 matched non-RA persons.<\/p>\n The researchers found that RA was independently associated with an increased lung cancer risk (adjusted hazard ratio [aHR], 1.58), which persisted in never-smokers (aHR, 1.65) and incident RA (aHR, 1.54). Prevalent RA-ILD (757 patients) was more strongly associated with lung cancer risk (aHR, 3.25) than RA without ILD (aHR, 1.57) compared with non-RA controls. Results were similar for both prevalent and incident RA-ILD (RA-ILD versus non-RA: aHR, 2.88).<\/p>\n “RA was associated with a >50 percent increased risk of lung cancer, and RA-ILD represented a particularly high-risk group with an approximate threefold increased risk,” the authors write. “Increased lung cancer surveillance in RA, and especially RA-ILD, may be a useful strategy for reducing the burden posed by the leading cause of cancer death.”<\/p>\n Several authors disclosed ties to the pharmaceutical industry.<\/p>\n Abstract\/Full Text\u00a0(subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n